Post-earnings recap
Reported
Wed, May 4, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Amicus Therapeutics is still struggling to improve its earnings per share, which fell short of expectations. The stock reacted negatively, declining by 1.34%, reflecting investor concerns about the company's financial health and lack of guidance. Without clear direction from management, investors may remain cautious about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | -11.43% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance and indicated that the company is focusing on long-term growth. They reiterated the importance of their pipeline but did not provide specific guidance.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in research and development.